- Home
- AMAL vs AVXL Comparison
AMAL vs AVXL Comparison
Compare AMAL & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- AVXL
- Stock Information
- Founded
- AMAL 1923
- AVXL 2004
- Country
- AMAL United States
- AVXL United States
- Employees
- AMAL N/A
- AVXL N/A
- Industry
- AMAL Commercial Banks
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMAL Finance
- AVXL Health Care
- Exchange
- AMAL Nasdaq
- AVXL Nasdaq
- Market Cap
- AMAL 937.6M
- AVXL 794.0M
- IPO Year
- AMAL 2018
- AVXL N/A
- Fundamental
- Price
- AMAL $33.35
- AVXL $10.60
- Analyst Decision
- AMAL Buy
- AVXL Strong Buy
- Analyst Count
- AMAL 3
- AVXL 2
- Target Price
- AMAL $36.50
- AVXL $44.00
- AVG Volume (30 Days)
- AMAL 198.6K
- AVXL 942.9K
- Earning Date
- AMAL 07-24-2025
- AVXL 08-05-2025
- Dividend Yield
- AMAL 1.70%
- AVXL N/A
- EPS Growth
- AMAL 9.81
- AVXL N/A
- EPS
- AMAL 3.36
- AVXL N/A
- Revenue
- AMAL $303,970,000.00
- AVXL N/A
- Revenue This Year
- AMAL $11.72
- AVXL N/A
- Revenue Next Year
- AMAL $12.48
- AVXL N/A
- P/E Ratio
- AMAL $9.78
- AVXL N/A
- Revenue Growth
- AMAL 7.13
- AVXL N/A
- 52 Week Low
- AMAL $25.03
- AVXL $4.00
- 52 Week High
- AMAL $38.19
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- AMAL 69.84
- AVXL 75.85
- Support Level
- AMAL $31.13
- AVXL $9.08
- Resistance Level
- AMAL $31.53
- AVXL $9.78
- Average True Range (ATR)
- AMAL 0.74
- AVXL 0.53
- MACD
- AMAL 0.25
- AVXL 0.19
- Stochastic Oscillator
- AMAL 94.07
- AVXL 95.03
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.